NAI Acne

Drug Profile

NAI Acne

Alternative Names: BI-Acne; BI-K-0376; CB-06-01; CB-06-04; NAI-003; NAI-Acne; VIC-acne

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vicuron Pharmaceuticals
  • Developer Cassiopea; NAICONS
  • Class Amides; Antiacnes; Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Peptide elongation factor Tu inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
  • 20 Jun 2003 Clinical data from a media release have been added to the adverse events section
  • 20 Jun 2003 Vicuron has completed a phase I trial in Acne in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top